5-chloro-2,3-diphenylpyrazine is the key intermediate of Selexipag. Selexipag is an oral Ip prostaglandin receptor agonist that relaxes vascular smooth muscles, dilates blood vessels, and reduces pulmonary artery pressure. It is recognized as an orphan drug by FDA. For the treatment of adult pulmonary hypertension patients.